Literature DB >> 11414737

OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo.

A R Weatherill1, J R Maxwell, C Takahashi, A D Weinberg, A T Vella.   

Abstract

OX40 costimulates T cells, increases activated T cell longevity, and promotes memory acquisition. T cells activated in vivo with agonist anti-OX40 and ovalbumin have a unique pattern of survival and cell division compared to control cells, but are able to respond to recall Ag equally well. BrdU incorporation shows that early cellular division rates of the anti-OX40-treated and the control groups are similar. Nevertheless, more BrdU(+) Ag-specific T cells accumulate in lymphoid tissue upon anti-OX40 administration. Thus, OX40 ligation does not necessarily lead to increased cell cycle entry, but promotes the accumulation of dividing cells. However, CFSE staining shows that OX40 ligation allows cells to progress through more cellular division cycles, while control cells stall or die. Moreover, OX40 ligation leads to a proportional decrease in apoptotic Ag-specific T cells. Thus, OX40 ligation boosts immunity by promoting an increase in the number cell cycles completed, thereby increasing the life span of Ag-activated CD4 T cells. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414737     DOI: 10.1006/cimm.2001.1783

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  15 in total

1.  Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.

Authors:  Lara Myers; Chikara Takahashi; Robert S Mittler; Robert J Rossi; Anthony T Vella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-14       Impact factor: 11.205

2.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 3.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Immunity, cancer and aging: lessons from mouse models.

Authors:  Cheryl E Myers; Noweeda N Mirza; Joseph Lustgarten
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

Review 5.  Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Authors:  Joseph M Ryan; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Expert Opin Biol Ther       Date:  2016-02-25       Impact factor: 4.388

6.  Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Authors:  Michael J Gough; Marka R Crittenden; MaryClare Sarff; Puiyi Pang; Steven K Seung; John T Vetto; Hong-Ming Hu; William L Redmond; John Holland; Andrew D Weinberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

Review 7.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 8.  Lymphoid tissue inducer cells: architects of CD4 immune responses in mice and men.

Authors:  M-Y Kim; K-S Kim; F McConnell; P Lane
Journal:  Clin Exp Immunol       Date:  2009-03-18       Impact factor: 4.330

Review 9.  The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors.

Authors:  Tiffany C Blair; Alejandro F Alice; Lauren Zebertavage; Marka R Crittenden; Michael J Gough
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

10.  Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.

Authors:  Edwin Bremer
Journal:  ISRN Oncol       Date:  2013-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.